ENTRY       D11534                      Drug
NAME        Odronextamab (USAN)
FORMULA     C6458H9950N1728O2020S46
EXACT_MASS  145501.6137
MOL_WEIGHT  145591.4592
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGRSLRL SCVASGFTFN DYAMHWVRQA PGKGLEWVSV ISWNSDSIGY
            ADSVKGRFTI SRDNAKNSLY LQMHSLRAED TALYYCAKDN HYGSGSYYYY QYGMDVWGQG
            TTVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
            PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPP
            VAGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE
            QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS
            QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSRLTVDK
            SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG
            (Light chain)
            EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG ASTRATGIPA
            RFSGSGSGTE FTLTISSLQS EDFAVYYCQH YINWPLTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (heavy chain)
            EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYTMHWVRQA PGKGLEWVSG ISWNSGSIGY
            ADSVKGRFTI SRDNAKKSLY LQMNSLRAED TALYYCAKDN SGYGHYYYGM DVWGQGTTVT
            VASASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPPVAGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ
            EGNVFSCSVM HEALHNRFTQ KSLSLSLG
            (Disulfide bridge: H22-H96, H141-L214, H154-H210, H233-h229, H236-h232, H267-H327, H373-H431, h22-h96, h137-L'214, h150-h206, h263-h323, h369-h427, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-CD20 antibody, Anti-CD3 antibody
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of B-cell malignancies
TARGET      CD20 [HSA:931] [KO:K06466]
            CD3E [HSA:916] [KO:K06451]
  PATHWAY   hsa04640(916+931)  Hematopoietic cell lineage
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D11534  Odronextamab (USAN)
                CD20
                 D11534  Odronextamab (USAN)
DBLINKS     CAS: 1801338-64-6
            PubChem: 384585510
///
